Gyre Therapeutics, Inc. (GYRE) vs Solid Biosciences Inc. (SLDB)

Gyre Therapeutics, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and Solid Biosciences Inc. are of similar size ($802.0M and $777.2M). Solid Biosciences Inc. has the higher net margin (0.00% vs −13.7%) and the higher return on invested capital (0.00% vs −8.51%). Across the 15 metrics below, Gyre Therapeutics, Inc. leads on 8 and Solid Biosciences Inc. on 7.

Valuation

Metric GYRE SLDB Biotechnology median
P/E n/m n/m 7.88
P/S 6.35 93.13 11.47
P/B 5.19 2.80 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 5.71 59.52 10.73
Earnings yield (2.72%) (26.20%) (28.84%)
Free cash flow yield (0.96%) (17.92%) (23.03%)

Profitability

Metric GYRE SLDB Biotechnology median
Gross margin 94.15% 0.00% 65.16%
Operating margin (10.53%) 0.00% 0.00%
Net margin (13.73%) 0.00% 0.00%
Free cash flow margin (6.12%) 0.00% 0.00%
Return on equity (11.75%) (65.50%) (57.72%)
Return on assets (9.08%) (56.83%) (49.22%)
Return on invested capital (8.51%) 0.00% 0.00%

Growth

Metric GYRE SLDB Biotechnology median
Revenue growth (TTM) 10.72% — 5.64%
EPS growth (last fiscal year) (60.00%) 34.97% —
Revenue growth, 5-year CAGR 40.96% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GYRE SLDB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.26 13.82 4.73
Net debt to EBITDA (3.74) 1.05 0.96

Dividend

Metric GYRE SLDB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GYRE SLDB Biotechnology median
Market cap 777.23m 802.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack